Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C
...evidence of any mitochondrial or other cellular toxicities that may be associated with some nucleoside analogs. Like RG7128, PSI-7851 has demonstrated pan
genotype activity in vitro .
Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing,...
Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th
Additional Clinical Studies Also Highlighted at pan
Randomized... "PIX 301 EXTEND trial") is being presented at the pan
Pacific Lymphoma conference by Dr. Richard Van der...gressive first-line therapy with CHOP-R.
Pacific Lymphoma Conference poster is available at...
Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting
...t restore the natural potential for cancer cells to undergo cell death (apoptosis). Ascenta's lead agent, AT-101, is an orally-active small molecule pan
Bcl-2 inhibitor (Bcl-2, Bcl-xL, and Mcl-1) currently in Phase 2 clinical trials in castrate resistant prostate cancer. The Company's preclinical pipe...
USAID Provides $5M in Emergency Support as Swine Flu Spreads
...ncy for International Development (USAID) announced today that it is providing an additional $5 million to the World Health Organization (WHO) and the pan
American Health Organization (PAHO) in emergency support for efforts to detect and contain the disease in Mexico.
"Since 2005, USAID has commit...
Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
... orally active, novel, small molecule inhibitor of pan
HDAC enzymes, that is currently in Phase I/II clin...ing and commercializing its innovative anti-cancer pan
HDAC inhibitor agents.
"This alliance with Se...tially commercialize our unique and differentiated pan
HDAC inhibitor product outside of the United State...
Semafore's SF1126 Exhibits Antitumor and Antiangiogenic Activity
...mor and antiangiogenic activity.
The paper, entitled "A Vascular Targeted pan
Inhibitor Prodrug, SF1126, with Antitumor and Ant...ancer model.
"The data further support our belief that SF1126 is a viable pan
inhibitor as we continue Phase I clinical trials," said Ed Jacobs,
Ascenta Therapeutics Highlights Multiple Data Presentations at
Upcoming AACR Annual Meeting
... growth by combined treatment with MD, PhD
Bcl-2 inhibitor AT-101 Ascenta
and docetaxel in hu...------------------------------- --------------
A novel pan
inhibitor of Bcl-2 and Xiongwen
CuraGen and TopoTarget Announce New Clinical Results With
Belinostat to be Reported at Upcoming Major Medical Meetings
...go, IL, June 2-5, 2007. A poster presentation will also be
made at the 2007 pan
Pacific Lymphoma Conference, which is being
hosted on the Island of Maui, H... session on Sunday, June
3rd\from 8:00 a.m. - 12:00 p.m.
Pacific Lymphoma Conference
-- A poster presentation entitled, "A Pha...
Global Rabies Treatment May be Possible with NanoViricides Drugs
...es against rabies that were presented along with the
successful BSL3 in vitro studies against a Clade 2 H5N1 virus at
the 23rd Annual Symposium of the pan
American Society for Clinical
Virology in Tampa, FL, on Wednesday, May 2. (Pan American Society
for Clinical Virology (PASCV): Clinical Virology Sympo...
Geron's Telomerase Inhibitor Cancer Drug Demonstrates Good
Pharmacokinetics and Tolerability in Phase I/II Trial
...s with chronic
lymphocytic leukemia (CLL), according to data presented today by
Alan Colowick, M.D., M.P.H., the company's president, oncology, at
Pacific Lymphoma Conference in Maui, Hawaii.
Favorable Pharmacokinetics; Pharmacodynamics Consistent with
A pharmacokinetic analysis o...
CuraGen Presents Update on Clinical Development Program for
A conference call is being hosted at 8:30 a.m. Eastern time on
June 12, 2007, to review these results including data presented at
the 2007 pan
Pacific Lymphoma Conference being held this week in
Maui, HI, and data presented at the 2007 American Society of
Clinical Oncology (ASCO) meeting.
Publication Confirms that EpCAM, the Target for Two of Micromet's
Product Candidates, Is Overexpressed on Cancer Stem Cells of
...ollins AT, Berry PA, Hyde C et al. Prospective identification of
tumorigenic prostate cancer stem cells. Cancer Res 2005; 65: 10946-51
CX, Zhu W, Cheng L. Implications of cancer stem cells in the
treatment of cancer. Future Oncol 2006; 2: 723-31
7 Baeuerle PA, Gires 0. E...